ABIVAX |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.58 EUR | -1.09% |
|
+2.97% | +48.47% |
| Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
| Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Chart calendar Abivax
37bca30149ea34f9eeaa7.tMcbs5DHHj7uOQqp0lu5nNptikK2gj22Pprn_y4X0WI.xaBz5fSmRF_cUVj6oRqK1pQ04SPU1m_zDP3WmV9nqBjsnSvq2IBNdYFDZQ~e00ef23f3ef2d92915a0d2fcc750f394
Upcoming events on Abivax
Past events on Abivax
| 2024-04-08 08:30 am | Q4 2023 Earnings Call |
| 2024-04-02 02:30 am | Q4 2023 Earnings Release |
| 2024-02-23 12:22 pm | European Crohn And Colitis Organisation Conference - Oral Presentation (DOP)-71 |
| 2024-02-23 06:40 am | European Crohn And Colitis Organisation Conference - Poster Presentaition-985 |
| 2024-02-23 06:40 am | European Crohn And Colitis Organisation Conference - Poster Presentation-025 |
| 2024-02-23 01:15 am | ECCO Congress |
| 2024-02-22 11:57 am | European Crohn And Colitis Organisation Conference - Oral Presentation (DOP)-12 |
| 2024-02-06 02:00 pm | Investor Meeting - Key Opinion Leaders |
| 2024-01-24 | Crohn’s & Colitis Congress |
| 2023-11-29 03:30 pm | Piper Sandler Healthcare Conference |
| 2023-10-19 | ACG Meeting |
| 2023-10-16 05:30 am | United European Gastroenterology Meeting - OP077 |
| 2023-10-15 09:30 am | United European Gastroenterology Week - Abstract Number : MP085 |
| 2023-10-15 04:00 am | United European Gastroenterology Week - Abstract Number : PP0892 |
| 2023-09-21 12:00 pm | Q2 2023 Earnings Release |
| 2023-06-05 04:00 am | Annual General Meeting |
| 2023-04-19 03:00 pm | Q4 2022 Earnings Release |
| 2023-03-03 06:30 am | ECCO Congress - Poster No - P001 |
| 2023-01-08 | JP Morgan Healthcare Conference |
| 2023-01-08 | LifeSci Partners Corporate Access Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 0,00 0,00 - | 1,70 7,07 -75.94% | 9,70 33,7 -71.2% | 0,10 1,65 -93.94% | 4,60 2,62 75.6% | 2,62 |
|
EBITDA Million EUR | Released Forecast Spread | -33,2 -31,4 -5.78% | -37,9 -32,3 -17.47% | -42,4 -47,3 10.35% | -56,6 -55,2 -2.49% | -127 -98,8 -28.23% | -148 |
|
EBIT Million EUR | Released Forecast Spread | -33,3 -23,8 -39.92% | -38,0 -35,8 -6.24% | -42,6 -47,7 10.63% | -56,6 -55,5 -1.98% | -127 -99,5 -28.03% | -149 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -34,9 -33,0 -5.76% | -40,1 -33,4 -20.17% | -45,6 -51,5 11.4% | -74,3 189 -139.32% | -148 -107 -37.8% | -142 |
|
Net income Million EUR | Released Forecast Spread | -30,6 -19,0 -61.48% | -37,6 -34,4 -9.26% | -41,4 -20,8 -99.18% | -69,8 -63,6 -9.83% | -147 -102 -44.64% | -160 |
|
EPS EUR | Released Forecast Spread | -2,51 -2,03 -23.54% | -2,62 -2,63 0.34% | -2,47 -2,87 13.84% | -3,13 -0,87 -259.77% | -3,43 -1,93 -77.72% | -2,56 |
| Announcement Date | 16/03/20 | 31/03/21 | 16/03/22 | 19/04/23 | 02/04/24 | - |
Quarterly results
| Fiscal Period | December | 2022 S1 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 2,40 2,30 4.35% | 2,30 | 2,30 | ||
|
EBIT Million EUR | Released Forecast Spread | -18,6 | ||||
|
Net income Million EUR | Released Forecast Spread | -29,6 | -52,0 | -95,4 -45,0 -112% | -93,3 | -102 |
|
EPS EUR | Released Forecast Spread | -1,45 | ||||
| Announcement Date | 15/09/22 | 29/09/23 | 02/04/24 | - | - |
More events
Past sector events for Abivax
Net sales - Quarter - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ABVX Stock
- Calendar Abivax
